Chimeric antigen receptor (CAR) T-cells have been a key focus in cancer research over recent years; however, T-cells are not the only cells into which it is possible to integrate a CAR. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden, William Wierda, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, discusses the recent creation of CAR NK-cells. He outlines the potential benefits of CAR NK-cells over CAR T-cells, explaining that toxicity from cytokine release is lower with CAR NK cells, and that CAR NK treatments do not have to be tailored to each specific patient, but can be cultivated in an off-the-shelf manner.
